Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jordan Gauthier

Showing results (31-40 of 87) with videos related to

Pageof 9
Sort By:
Journal of Immunotherapy (Hagerstown, Md. : 1997)|August 9, 2021
CMV and HSV Pneumonia After Immunosuppressive Agents for Treatment of Cytokine Release Syndrome Due to Chimeric Antigen Receptor-modified T (CAR-T)-Cell ImmunotherapyMadeleine R Heldman, Jimmy Ma, Jordan Gauthier, et al.
Transplantation and Cellular Therapy|March 25, 2026
Fear of cancer recurrence in hematopoietic cell transplantation survivors: fear of cancer recurrence in HCT survivorsEmily C Liang, Megan J Shen, Rachel B Salit, et al.
Bulletin Du Cancer|November 28, 2017
[Allogeneic haematopoietic cell transplantation for indolent lymphomas: Guidelines from the Francophone Society Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]Jordan Gauthier, Sylvain Chantepie, Krimo Bouabdallah, et al.
Bulletin Du Cancer|November 28, 2017
[Allogeneic haematopoietic cell transplantation for diffuse large B cell lymphoma: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]Jordan Gauthier, Sylvain Chantepie, Krimo Bouabdallah, et al.
Bulletin Du Cancer|November 25, 2017
[Use of alternative donors for allogeneic haematopoietic cell transplantation in lymphoid neoplasms: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]Jordan Gauthier, Sylvain Chantepie, Krimo Bouabdallah, et al.
Bulletin Du Cancer|November 28, 2017
[Allogeneic hematopoietic cell transplantation for Hodgkin's disease, mantle cell lymphoma and other rare entities: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]Jordan Gauthier, Sylvain Chantepie, Krimo Bouabdallah, et al.
Blood Advances|January 10, 2024
Answering the "Doctor, can CAR-T therapy cause cancer?" question in clinicRahul Banerjee, Christina Poh, Alexandre V Hirayama, et al.
Blood|October 25, 2019
High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapyAlexandre V Hirayama, Jordan Gauthier, Kevin A Hay, et al.
Blood Advances|November 4, 2022
A novel polymer-conjugated human IL-15 improves efficacy of CD19-targeted CAR T-cell immunotherapyAlexandre V Hirayama, Cassie K Chou, Takahiro Miyazaki, et al.
Haematologica|June 19, 2025
Extramedullary disease is associated with severe toxicities following B-cell maturation antigen CAR T-cell therapy in multiple myelomaAndrew J Portuguese, Emily C Liang, Jennifer J Huang, et al.
Pageof 9

Showing results (31-40 of 87) with videos related to

Sort By:
Pageof 9
Journal of Immunotherapy (Hagerstown, Md. : 1997)|August 9, 2021
CMV and HSV Pneumonia After Immunosuppressive Agents for Treatment of Cytokine Release Syndrome Due to Chimeric Antigen Receptor-modified T (CAR-T)-Cell ImmunotherapyMadeleine R Heldman, Jimmy Ma, Jordan Gauthier, et al.
Transplantation and Cellular Therapy|March 25, 2026
Fear of cancer recurrence in hematopoietic cell transplantation survivors: fear of cancer recurrence in HCT survivorsEmily C Liang, Megan J Shen, Rachel B Salit, et al.
Bulletin Du Cancer|November 28, 2017
[Allogeneic haematopoietic cell transplantation for indolent lymphomas: Guidelines from the Francophone Society Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]Jordan Gauthier, Sylvain Chantepie, Krimo Bouabdallah, et al.
Bulletin Du Cancer|November 28, 2017
[Allogeneic haematopoietic cell transplantation for diffuse large B cell lymphoma: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]Jordan Gauthier, Sylvain Chantepie, Krimo Bouabdallah, et al.
Bulletin Du Cancer|November 25, 2017
[Use of alternative donors for allogeneic haematopoietic cell transplantation in lymphoid neoplasms: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]Jordan Gauthier, Sylvain Chantepie, Krimo Bouabdallah, et al.
Bulletin Du Cancer|November 28, 2017
[Allogeneic hematopoietic cell transplantation for Hodgkin's disease, mantle cell lymphoma and other rare entities: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]Jordan Gauthier, Sylvain Chantepie, Krimo Bouabdallah, et al.
Blood Advances|January 10, 2024
Answering the "Doctor, can CAR-T therapy cause cancer?" question in clinicRahul Banerjee, Christina Poh, Alexandre V Hirayama, et al.
Blood|October 25, 2019
High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapyAlexandre V Hirayama, Jordan Gauthier, Kevin A Hay, et al.
Blood Advances|November 4, 2022
A novel polymer-conjugated human IL-15 improves efficacy of CD19-targeted CAR T-cell immunotherapyAlexandre V Hirayama, Cassie K Chou, Takahiro Miyazaki, et al.
Haematologica|June 19, 2025
Extramedullary disease is associated with severe toxicities following B-cell maturation antigen CAR T-cell therapy in multiple myelomaAndrew J Portuguese, Emily C Liang, Jennifer J Huang, et al.
Pageof 9